North America Biodefense Market By Product (Anthrax, Smallpox, Botulism, Radiation/nuclear, and Other Products), By Country, Industry Analysis and Forecast, 2020 - 2026
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the North America Biodefense Market
Market Report Description
The North America Biodefense Market would witness market growth of 5% CAGR during the forecast period (2020-2026). Biodefense is considered as the steps taken to re-establish the biosecurity of a group of organisms that are confronting biological threats or infectious diseases. It refers to an efficient public health care system with robust disease surveillance and quick actions designed to manage biological threats, to prevent the spread of disease, and offer medical care. The rising threat of biological weapons & nuclear-armed ICBM, supportive governmental initiatives, and expansion in the naturally occurring outbreaks, are leading factors pushing the market growth. Although, low investment in R&D by the government in emerging and underdeveloped countries, is anticipated to hamper the development of the biodefense market during the forecast years.
Bioterrorism refers to the utilization of biological agents that are damaging the mankind. Biodefense means the usage of medical steps in order to save mankind from bioterrorism, including interventions like drugs and vaccinations. Moreover, research and public health preparations have seen development to counter biological attacks. Some of the past incidents of bioterrorism carried out by viral agents like botulism, anthrax, and smallpox, have made biodefense a significant focus area for research by countries to defend against bioterrorism.
Governments’ agencies were forced to develop and strategize biodefense programs due to repeated outbreaks of the Ebola and Zika virus, hence aid in planning and responding during future outbreaks. In 2018, the U.S. government issued the National Biodefense Strategy to manage the threats of biological incidents by identifying and preventing bio treats at its initial stage, encouraging biomedical innovation, and enhancing emergency response.
Based on Product, the market is segmented into Anthrax, Smallpox, Botulism, Radiation/nuclear, and Other Products. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Xoma Corporation, Altimmune, Inc., Emergent BioSolutions, Inc., Dynavax Technologies Corporation, SIGA Technologies, Inc., Elusys Therapeutics, Inc., Ichor Holdings, Ltd., Cleveland BioLabs, Inc., Bavarian Nordic A/S and Alnylam Pharmaceuticals, Inc.
Scope of the Study
Market Segments Covered in the Report:
- Other Products
- Rest of North America
- Xoma Corporation
- Altimmune, Inc.
- Emergent BioSolutions, Inc.
- Dynavax Technologies Corporation
- SIGA Technologies, Inc.
- Elusys Therapeutics, Inc.
- Ichor Holdings, Ltd.
- Cleveland BioLabs, Inc.
- Bavarian Nordic A/S
- Alnylam Pharmaceuticals, Inc.
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free